of S&P 500 names capturing two or more of Kostin's themes: GT , GM , PCLN , AMZN , CMCSA , LOW , DG , TSN , ADM , CVS , AVP , WAG , PXD , HAL , JPM , BAC , SCHW , PNC , MS , C , GNW , LNC , MET , THC , AET , UNH , ESRX , HUM , WLP , BIIB , GILD , DAL
By Robert FitzPatrick : On March 12, 2014, Herbalife (NYSE: HLF ) announced it received a Civil Investigative Demand from the Federal Trade Commission, FTC. This FTC action was generally viewed as being prompted, at least in part, by the critical information published by the hedge fund, Pershing ...
from its Phase 2 clinical trial evaluating AVP -923 for the treatment of agitation in ..... mean reduction from baseline of 47% for AVP -923 compared to 22% for placebo in Stage ..... vs 6.7%, respectively in Stage 2. AVP -923 is a combination of two well-characterized
peeling off some tech and momentum favorites. The partial list below represents stocks up at least 1% on the day with a dividend yield of over 2%. Back in favor: AVP , KO , MO , RAI , BUD , PF , BGS , DPS , CPB , LO , DF . Post your comment!
active over passive. The higher the relative breadth percentage, the greater the tendency for active to outperform passive. AvP 3yr = excess return of active over passive during rolling 3-year periods. Source: Haver Analytics, Morningstar, Fidelity
previous session at 6.74 and closing on the 15th at 12.40 on the announcement of a successful phase-II trial of their drug AVP -923 , which has until now been used to treat patients with pseudobulbar affect under the brand name Neudexta, for use in patients
Avanir Pharmaceuticals (NASDAQ: AVNR ) is off 6% premarket on robust volume as traders begin to take profits from yesterday's ultra-bullish 85% jump on turnover of ~89M shares in response to positive Phase 2 trial results for AVP -923. Post your comment!
pop after it reported positive Phase 2 results for AVP -923. Concert's license agreement with Avanir pertains ..... modified dextromethorphan (d-DM) which is what AVP -786 is based on. AVP -923 is a combination of dextromethorphan and quinidine
response to its announcement of positive results from its Phase 2 trial evaluating AVP -923 for the treatment of agitation in patients with Alzheimer's disease. AVP -923 achieved the primary endpoint of a statistically significant reduction in
By Rogier van Vlissingen : Herbalife (NYSE: HLF ) continues to amaze. The stock has been sliding on low volumes for quite a while, then we had an acceleration in volume for a few days and a continuing slide, with two 52-week lows posted on successive days. At the open on 9/11, it went up a bit, ...